Blackstone Backs Pfizer’s Monthly GLP-1 Program as Databento Reaches $1.1 Billion Valuation

Blackstone Life Sciences has agreed to provide Pfizer with up to $1.5 billion to finance development of a monthly GLP-1 receptor agonist, highlighting the growing role of private capital in funding late-stage pharmaceutical research. Separately, financial-data platform Databento raised $100 million in Series C funding at a $1.1 billion valuation.

The Pfizer transaction, reported by Axios on November 13, reflects a shift in how drug developers may finance expensive Phase 2 and Phase 3 clinical trials. Rather than relying solely on traditional pharmaceutical balance sheets or public-market fundraising, Pfizer is working with a private investment firm to support development of a potential next-generation obesity treatment.

Blackstone Expands Private Capital’s Role in Drug Development

Blackstone Life Sciences’ commitment is tied to the development program and is intended to finance research and clinical work for Pfizer’s monthly GLP-1 candidate. The arrangement does not represent a completed product launch or a guarantee of regulatory approval. Its value will depend on the program’s clinical progress, regulatory outcomes and eventual commercial potential.

For investors, the deal illustrates how private-equity and alternative-asset managers are seeking exposure to large pharmaceutical markets while helping established drug companies share development costs and risk. GLP-1 medicines have become one of the most closely watched areas in healthcare investment because of demand for treatments targeting obesity and related metabolic conditions.

The structure also signals increasing competition for differentiated therapies. Pfizer has been working to strengthen its position in the GLP-1 market, where rival drugmakers have already established major commercial franchises. Financing support can give companies additional flexibility to advance promising candidates, but it does not remove the clinical and regulatory risks inherent in drug development.

Databento Raises $100 Million at $1.1 Billion Valuation

Databento, a financial-market data platform, raised $100 million in Series C funding at a valuation of $1.1 billion, according to Axios. The round was led by Huagai Capital and Bayland Capital, with participation from a broad group of venture and strategic investors.

The financing gives Databento additional capital to expand its market-data infrastructure and products for institutional and professional users. Its valuation places the company among a growing group of private financial-technology businesses attracting substantial funding as investors seek exposure to the modernization of market-data delivery and analytics.

Databento’s fundraising also underscores the continuing appetite for specialized infrastructure serving financial institutions. Market participants increasingly require faster access to large volumes of exchange and alternative data, while technology providers compete to lower distribution costs and improve data usability.

Together, the two transactions show investors directing private capital toward businesses with potentially large recurring markets: pharmaceutical treatments with substantial commercial demand and financial infrastructure that supports institutional trading and research. Both developments remain subject to execution risk, including clinical outcomes for Pfizer and customer growth, competition and operating performance for Databento.